Eiger BioPharmaceuticals Announces Initiation of CLEAN-1 HCV Phase 1b Trial
Proof of Concept Study Investigating NS4B-RNA Binding Inhibitor
13-Aug-2009 -
Eiger BioPharmaceuticals, Inc. announced that the first patients have been dosed in a clinical trial in patients chronically infected with the hepatitis C virus (HCV). The trial, run in centers in Australia and New Zealand, will investigate the antiviral effect of clemizole monotherapy in the ...
clinical trials
drug resistance
Glenn
+5